AbbVie (ABBV) Q4 Earnings Beat, Raises Sales View for Key Drugs

AbbVie Inc. (ABBV) reported adjusted earnings of $2.79 per share for fourth-quarter 2023, beating the Zacks Consensus Estimate of $2.76. The reported earnings also exceeded the guidance of $2.72-$2.76. However, earnings declined 22.5% year over year.ABBV’s revenues of $14.30 billion beat the Zacks Consensus Estimate of $14.05 billion. Sales declined 5.4% year over year, both on a reported basis and an operational basis. The downside was caused by lower sales of Humira and Imbruvica, which was partially offs ...